Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Intec Pharma Ltd. (NTEC)
|
Add to portfolio |
|
|
|
| Price: |
$4.12
| | Metrics |
| OS: |
4.5
|
M
| |
-97
|
% ROE
|
| Market cap: |
$18.6
|
M
| |
-859
|
% ROIC
|
|
Net cash:
|
$14.7
|
M
| |
$3.26
|
per share
|
|
EV:
|
$3.88
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($12.6)
|
M
| |
|
|
|
EBIT
|
($13.8)
|
M
| |
|
|
| EPS |
($2.11)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 0.0 | 1.5 | 0.9 | 0.3 | 15.4 | 7.6 | 5.2 | 5.2 |
| Revenue growth | -100.0% | 76.1% | 197.9% | -98.1% | 103.7% | 45.4% | -0.1% | |
| Cost of goods sold | 0.0 | 0.0 | 0.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 1.5 | 0.0 | 0.0 | 15.4 | 7.6 | 5.2 | 5.2 |
| Gross margin | | 100.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 6.7 | 26.7 | 35.4 | 24.3 | 26.1 | 12.3 | 8.4 | 7.8 |
| General and administrative | 7.1 | 8.3 | 7.9 | 5.1 | 3.1 | 2.8 | 2.6 | 2.4 |
| EBIT | -13.8 | -33.4 | -43.3 | -29.4 | -13.8 | -7.6 | -5.8 | -5.0 |
| EBIT margin | | -2229.7% | -5085.4% | -10293.4% | -89.8% | -100.4% | -111.4% | -96.9% |
| Pre-tax income | -14.0 | -47.0 | -43.4 | -28.9 | -13.4 | -7.2 | -5.7 | -5.1 |
| Income taxes | 0.1 | 0.6 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -14.1 | -47.6 | -43.5 | -28.9 | -13.4 | -7.2 | -5.7 | -5.1 |
| Net margin | | -3173.3% | -5110.7% | -10108.0% | -86.9% | -95.1% | -109.6% | -98.1% |
| |
| Diluted EPS | ($4.08) | ($28.18) | ($1.40) | ($1.64) | | | | |
| Shares outstanding (diluted) | 3.5 | 1.7 | 31.2 | 17.7 | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|